Novel Coagulation Test Detects Anticoagulation Resistance and Is Associated With Thrombotic Events in Pediatric Patients Requiring Extracorporeal Membrane Oxygenation

• Published in: Critical care explorations Vol. 4; no. 10; p. e0776
• Main Authors: Frydman, Galit H, Berger, Barry M, Kostousov, Vadim, Bruzdovski, Karen, Papageorgiou, Dimitrios P, Navaei, Amir, Hui, Shiu-Ki Rocky, Teruya, Jun
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer 01-10-2022
• Subjects: ECMO; heparin; VAD; bivalirudin; thrombosis; anticoagulation
• ISSN: 2639-8028; 2639-8028
• DOI: 10.1097/CCE.0000000000000776

Bivalirudin, an IV direct thrombin inhibitor, and unfractionated heparin (UFH) are frequently used anticoagulants in the pediatric critical care setting. An accurate, specific, point-of-care test to quantify and detect anticoagulation resistance is not currently available. This study evaluates the ability of a rapid (< 10 min), micro-volume (
50 uL) coagulation test to detect and quantify the anticoagulation effect of bivalirudin and UFH using a functional, clot time endpoint in pediatric critical care patients.
Single-site retrospective laboratory sample analysis and chart review.
A 105-bed pediatric and cardiac ICUs delivering extracorporeal membrane oxygenation.
Forty-one citrated, frozen, biobanked plasma specimens comprising 21 with bivalirudin and 20 with UFH from 15 anticoagulated pediatric patients were analyzed. Thirteen patients were on extracorporeal membrane oxygenation, one had a submassive pulmonary embolism, and one was on a left ventricular assist device.
None.
A Clotting Time Score (CTS) was derived on each sample. The CTS detected patients that had developed a pathologic clotting event with 100% sensitivity and 82% specificity compared with prothrombin time with 25% sensitivity/76% specificity and activated partial thromboplastin time with 0% sensitivity/0% specificity. Additionally, the CTS detected subtherapeutic anticoagulation in response to UFH in patients that were clinically determined to be UFH resistant requiring alternative anticoagulation with bivalirudin.
The CTS appears to be a clinically valuable indicator of coagulation status in patients treated with either UFH or bivalirudin. Results outside of the therapeutic range due to inadequate dosing or anticoagulation resistance appeared to be associated with clot formation. CTS testing may reduce the risk of anticoagulation-related complications via the rapid identification of patients at high risk for pathologic thrombotic events.